Shots: Yuhan to receive $40M as upfront & near-term payment and up to $830M milestones and royalties on sales. BI focuses to develop NASH treatment targeting key drivers of the […]readmore
Tags : Nonalcoholic Steatohepatitis
Shots: Insitro to receive $15M upfront, $35M near term operational milestone, $200M as preclinical, development, regulatory and commercial milestones on each 5 targets & royalties on sales. Insitro has also […]readmore
Shots: The P-III STELLAR-4 study involves assessing of Selonsertib (18mg, 6mg, qd) vs PBO (qd) in patients with compensated cirrhosis (F4) due to NASH for 240 wks. The P-III study […]readmore